Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Co-Founder & Managing Partner, Trekk Venture Partners
Vikas is a founder and Managing Partners of Trekk Venture Partners, an emerging biotech venture capital fund. He has been working in the biotech industry for 20 years, with a particular focus on corporate strategy, capital formation, corporate partnerships, and M&A for early stage therapeutics companies. Prior to co-founding Trekk, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and Series A investor before ultimately joining full-time in 2019. Vikas led Pandion through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One. During his time at SR One, Vikas invested in and served on the boards of 19 early stage biotech companies including Morphic Therapeutics (NASDAQ: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics (Tyk2 program acquired by Takeda), Turning Point (acquired by BMS), Spero Therapeutics (tebipenem pivoxil HBr acquired by GSK) and Pandion (acquired by Merck). River Vision and Horizon developed Tepezza (teprotumumab) a new standard of care in the treatment of Grave’s Orbitopathy and the first therapy ever approved for the indication. Previously, Vikas was a Consultant at McKinsey & Co’s Pharmaceutical practice in New Jersey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals. He is a member of the Kauffman Fellows Society (Class 17). Vikas earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in Neurobiology from Harvard University. Vikas truly believes that partnerships can be critical to the successful development of new medicines. In his free time, he hosts an interview series on the Timmerman Report with biotech business development executives about the deals they have worked on and lessons learned. Vikas lives in Somerville with his wife (who also works in the biotech industry) and two daughters.

Brought to you by